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ttp://dx.doi.org/10.1016/j.ajpath.2014.01.006Interferon (IFN)-g displays a critical role in tuberculosis (TB), modulating the innate and adaptive
immune responses. Previously, we reported that secretory leukocyte protease inhibitor (SLPI) is a
pattern recognition receptor with anti-mycobacterial activity against Mycobacterium tuberculosis
(Mtb). Herein, we determined whether IFN-g modulated the levels of SLPI in TB patients. Plasma
levels of SLPI and IFN-g were studied in healthy donors (HDs) and TB patients. Peripheral blood
mononuclear cells from HDs and patients with TB or defective IFN-g receptor 1* were stimulated with
Mtb antigen and SLPI, and IFN-gR expression levels were measured. Both SLPI and IFN-g were
signiﬁcantly enhanced in plasma from those with TB compared with HDs. A direct association between
SLPI levels and the severity of TB was detected. In addition, Mtb antigen stimulation decreased the
SLPI produced by peripheral blood mononuclear cells from HDs, but not from TB or IFN-gR patients.
Neutralization of IFN-g reversed the inhibition of SLPI induced by Mtb antigen in HDs, but not in TB
patients. Furthermore, recombinant IFN-g was unable to modify the expression of SLPI in TB patients.
Finally, IFN-gR expression was lower in TB compared with HD peripheral blood mononuclear cells.
These results show that Mtb-induced IFN-g down-modulated SLPI levels by signaling through the IFN-
gR in HDs. This inhibitory mechanism was not observed in TB, probably because of the low expression
of IFN-gR detected in these individuals. (Am J Pathol 2014, 184: 1268e1273; http://dx.doi.org/
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Although protective immunological mechanisms against
Mycobacterium tuberculosis (Mtb) are not fully understood,
resistance to mycobacterial infections is primarily mediated
by the interaction of antigen-speciﬁc T cells and macro-
phages.1,2 This interaction depends on the cross talk of
cytokines produced by these cells, and interferon (IFN)-g is
essential for protection.2,3 Thus, during the immune responsestigative Pathology.
.
SLPI and IFN-g Receptor in Tuberculosisof the host against Mtb, IFN-g produced by type 1 helper
T cells is recognized by its receptor on macrophages. The
IFN-g receptor (IFN-gR) is composed of two ligand-binding
IFNGR1 chains associated with two signal-transducing
IFNGR2 chains, and an associated signaling machinery.2e5
IFN-g binds to its receptor and activates macrophages to
efﬁcient killing of intracellular mycobacteria. In humans, the
loss-of-function mutations in IFNGR1 or IFNGR2 genes are
closely associated with severe susceptibility to poorly viru-
lent mycobacteria highlighted in childhood.4,6,7
Secretory leukocyte protease inhibitor (SLPI) is a serine
protease inhibitor secreted by inﬂammatory and epithelial
cells, mainly in the respiratory tract mucosa, and it is pri-
marily active against neutrophilic elastase, cathepsin G,
trypsin, and chymotrypsin.8 The expression and secretion of
SLPI are down-modulated during chronic obstructive pul-
monary disease.9e11 In addition, cathepsins B, L, and S and
cigarette smoke exposure result in the cleavage and inacti-
vation of SLPI.12,13 Moreover, it has been demonstrated that
IFN-g is a prominent stimulator of cathepsins and matrix
metalloproteinase-12 and an inhibitor of SLPI.14 Remark-
ably, SLPI may also function as an endogenous immuno-
modulatory, anti-inﬂammatory, and/or antimicrobial
substance.15e18 The antimicrobial effects of SLPI against
several bacteria have been demonstrated.15 In particular,
Nishimura et al17 described that recombinant mouse SLPI
inhibited the growth of bacillus Calmette-Guérin (BCG) and
Mtb through the disruption of the mycobacterial cell wall
structure. Furthermore, we reported that human SLPI is a
secreted pattern recognition receptor for mycobacteria that
increases both the phagocytosis and killing of the path-
ogen.18 Remarkably, exposure of murine peritoneal mac-
rophages to Mtb led to an increase in SLPI secretion.19
Thus, given the anti-inﬂammatory and anti-mycobacterial
roles of SLPI in humans and taking into account the fact
that SLPI is inhibited by IFN-g,20 a crucial cytokine in the
protective immunity against Mtb, herein we studied the
effect of IFN-g on the expression of SLPI during human
active disease.
Materials and Methods
Subjects
Adult patients with active TB were evaluated at the Hospital
F. J. Muñiz (Buenos Aires, Argentina). The diagnosis was
established on the basis of clinical and radiological data,
together with the identiﬁcation of acid-fast bacilli in sputum.
Physical examination, complete blood cell count, electrolyte
determination, chest X-ray, and HIV test were performed for
each patient. According to the extent and type of X-ray
ﬁndings, the severity of lung involvement was classiﬁed
into three groups: mild (a single lobe involved, and without
visible cavities), moderate (unilateral involvement of two or
more lobes and cavities, if present, reaching a total diameter
4 cm), and severe (massive involvement of both lungs andThe American Journal of Pathology - ajp.amjpathol.orgmultiple cavities).21 Exclusion criteria included a positive
HIV test result or the presence of concurrent infectious
diseases. Healthy adult donors (HDs), individuals with no
history of TB who had received BCG vaccination at birth,
were also included in the study. The demographic charac-
teristics of HD individuals and TB patients are shown in
Supplemental Table S1. All participants provided a written
informed consent for the collection of samples and subse-
quent analysis. All of the protocols were approved by the
Ethical Committee of the Hospital F. J. Muñiz and the In-
ternational Review Board Fundación Huésped. Two patients
with inactivating mutations of the IFNGR1 were also
included. Patient 1 (P1), a ﬁrst child born from non-
consanguineous Mestizo Mexican parents, received BCG
vaccine at birth without adverse reactions. At 2 years old, P1
was diagnosed with cutaneous TB and treated with anti-
mycobacterial drugs during a year, with total cure of the
skin lesions. At age 13 years, P1 required treatment for
uveitis in the left eye during 1 year, with remission of
symptoms. At the time of writing this article, the patient was
20 years old and reported doing well, with no infections.
Patient 2 (P2), the second child from the same family,
received BCG vaccine at birth, which caused him axillary
lymphadenitis. A biopsy specimen of the lymph nodes was
positive for acid-fast bacilli, and he received treatment with
anti-TB drugs during 1 year, with complete remission. He
did not have recurrence of any mycobacterial infection. At
the time of writing this article, the patient was 15 years old,
and he reported doing well, with no infections. Both P1 and
P2 were studied to seek for immunological defects, and
pieces of evidence were found about partial response to
IFN-g. Molecular studies demonstrated a heterozygous
mutation in the IFNGR1 gene in both patients, affecting
intracellular signaling. Epstein-Barr virusetransformed B-
cell lines from both patients had been experimentally tested
and showed no phosphorylation of Stat-1 when cells were
treated with IFN-g. Phosphorylation of Stat-1 in response to
IFN-a demonstrated the speciﬁcity in the IFNGR defect.
Antigen
In vitro stimulation of cells throughout the study was per-
formed with a cell lysate from the virulent Mtb H37Rv
strain prepared by probe sonication [Mtb-antigen (Ag)] and
obtained through the NIH Biodefense and Emerging In-
fections Research Resources Repository, National Institute
of Allergy and Infectious Diseases (Bethesda, MD) (NIH:
Mtb, strain H37Rv, whole cell lysate, NR-14822).
Blood Samples, Cell Isolation, and Culture
Blood samples were obtained between 8 and 10 AM in
heparinized tubes. Plasma was obtained and preserved at
20C. Peripheral blood mononuclear cells (PBMCs) were
isolated over density gradient centrifugation on Ficoll-Paque
(Amersham Biosciences, Piscataway, NJ). Then, 1  1061269
Figure 1 Plasma levels of SLPI in HDs and TB patients. A: Plasmatic SLPI
levels. SLPI levelswereanalyzedby sandwichELISA inplasma fromHDs (nZ23)
and TB patients (n Z 29). B: Association between plasma SLPI levels and
disease severity. HD data from A were plot as subjects who had been in contact
with TB patients (HCs) and those who had not been in contact with patients
(HDs). Patients with TB were also classiﬁed as mild, moderate, and severe.21
Student’s t-test (A) or analysis of variance post hoc Dunnett’s multiple com-
parisons test (B) was used. *P < 0.05, between severe and mild TB patients;
**P < 0.01 (A); yyP < 0.01 between severe TB patients and HDs or HCs (B).
Tateosian et alPBMCs/mL were cultured with RPMI 1640 medium
(Gibco, Gaithersburg, MD) supplemented with L-glutamine,
gentamicin, and 10% fetal bovine serum (Gibco). PBMCs
were incubated in the presence or absence of 10 mg/mLMtb-
Ag for 48 hours. Afterward, media were removed and cell-
free supernatants were assayed for SLPI by a homemade
enzyme-linked immunosorbent assay (ELISA). In some
experiments, 30 minutes before the stimulation with the
antigen, PBMCs were incubated with 15 mg/mL blocking
antibody against IFN-g [functional grade mouse (IgG1k)
anti-human IFN-g, clone MD-1; eBioscience, San Diego,
CA] or 15 mg/mL puriﬁed mouse IgG1k isotype control
(clone P3.6.2.8.1; eBioscience). In other experiments,
PBMCs were incubated in the presence or absence of 7.5
ng/mL recombinant IFN-g (rIFN-g; eBioscience).Figure 2 Correlation between the levels of IFN-g and SLPI in HDs and TB pati
results for plasmatic IFN-g levels from HDs (n Z 15) and TB patients (n Z 19).
(white circles; n Z 15) and TB patients (black circles; n Z 19). Student’s t-test
1270SLPI and IFN-g Determination
The levels of IFN-g were determined by sandwich ELISA
(lower limit of detection, 36 pg/mL) following the manu-
facturer’s instructions (eBioscience). The concentrations of
SLPI in plasma and cell culture supernatants were measured
by sandwich ELISA, with a lower limit of detection of 0.31
ng/mL, as previously described.22
Real-Time PCR
PBMCs were stimulated in the presence or absence ofMtb-Ag
for 0, 16, 24, and 48 hours. Total RNA was then isolated
with TRIzol (Invitrogen Life Technologies, Buenos Aires,
Argentina), followed by reverse transcription, according to the
manufacturer’s instructions (Promega, Madison, WI). Real-
time PCR was performed with Mezcla Real Master Mix (Bio-
dynamics SRL, Buenos Aires, Argentina) and speciﬁc primers
for human IFN-gR (Integrated DNA Technologies, Bio-
dynamics, Buenos Aires, Argentina). RelativeRNA expression
was normalized to the expression of GAPDH (encoding
glyceraldehyde-3-phosphate dehydrogenase), calculated by the
change-in-threshold (DDCT) method. The primers used for
IFN-gR and GAPDH were as follows: 50-TGTGTATGTGA-
GAATGAACGGAAG-30 (forward) and 50-AGGATACTGG-
AATCGCTAACTGG-30 (reverse); and 50-TGATGACATC-
AAGAAGGTGGTGAAG-30 (forward) and 50-TCCTTGGA-
GGCCATGTAGGCCAT-30 (reverse), respectively.
Statistical Analysis
Analysis of variance and post hoc Dunnett’s multiple compar-
isons test were used as indicated in the ﬁgure legend.Wilcoxon
rank sum testwas used to analyze differences between unpaired
samples. Correlation analyses were performed using the Pear-
son correlation test. P < 0.05 was considered signiﬁcant.
Results
Expression of SLPI in HDs and TB Patients
Exposure of murine peritoneal macrophages to Mtb led to an
increase in SLPI secretion.19 To assess whether Mtb alsoents. IFN-g plasma levels in HD and TB patients were determined. A: ELISA
B: Correlation between the levels of SLPI and IFN-g in the plasma of HDs
(A) and Pearson correlation coefﬁcient (B). *P < 0.05.
ajp.amjpathol.org - The American Journal of Pathology
Figure 3 Effect of IFN-gon SLPI levels.A:PBMCs fromHDs and TBpatients
were cultured for 48 hours in the presence or absence of 10 mg/mL Mtb-Ag,
7.5 ng/mL rIFN-g, and 15 mg/mL blocking monoclonal antibody against
IFN-g (30 minutes) or 15 mg/mL isotype control. B: PBMCs from IFNGR1* pa-
tients and age-matchedHDswere cultured for 5 days in the presenceor absence
of Mtb-Ag. A and B: After culture, medium was removed and cell-free super-
natants were collected and assayed for SLPI. Data are expressed as the
means SEM in HDs (nZ 6) and TB patients (nZ 6) (A) and in HDs (nZ 4)
and IFNGR1* patients (n Z 2) (B). Analysis of variance post hoc Dunnett’s
multiple comparisons test. C and D: Real-time PCR for IFN-gR expression on
PBMCs. C: PBMCs were obtained from patients with TB classiﬁed as mild
(nZ 6), moderate (nZ 6), and severe (nZ 6)21 and HD subjects (nZ 6).
IFN-gR expression was determined by quantitative real-time PCR. Values are
represented as fold of increase using the comparative method for relative
quantiﬁcation. Expression of IFN-gR was calculated as follows (a comparative
method for relative quantiﬁcation after normalization to GAPDH expression):
Fold increaseZ2DDCt; where DCtZ ½Ct ðIFN-gRÞ  Ct ðGAPDHÞ and
DDCtZ ½DCtTB DCtHD: Mann-Whitney test. C: Signiﬁcant differences
between mild and severe TB patients. D: PBMCs from patients with TB (nZ 9)
and HDs (n Z 11) were cultured by 16, 24, or 48 hours in the presence or
absence of Mtb-Ag. Cells were harvested, and IFN-gR expression was deter-
mined as in C. Expression of IFN-gR was calculated as follows (a comparative
method for relative quantiﬁcation after normalization to GAPDH expression):
Fold increaseZ 2DDCt; whereDCtZ ½Ct ðIFN-gRÞ  Ct ðGAPDHÞ andDDCt
Z [DCtstimulatedDCtunstimulated]. Unpaired t-test, for signiﬁcant differ-
ences between HDs and TB patients at 16 hours and for signiﬁcant differences
between 16 and 48 hours in TB patients. *P < 0.05 (AeD); yyP < 0.01, for
signiﬁcant differences between 16 and 48 hours in HDs (D).
SLPI and IFN-g Receptor in Tuberculosisinduces the production of SLPI in humans, we analyzed the
levels of SLPI in plasma of TB patients and HD subjects.
Figure 1A shows that SLPIwas signiﬁcantly higher in patients’
plasma compared with HDs. To determine a potential rela-
tionship between SLPI concentration and the severity of TB,
we investigated the levels of SLPI in patients classiﬁed ac-
cording to their radiological lesions (mild, moderate, and se-
vere), as previously described.21 Interestingly, we found that
patients with severe TB displayed higher levels of SLPI
compared with patients with mild TB and with subjects in
contact with TB patients (HCs) and HDs (Figure 1B). Patients
with moderate TB showed slightly higher levels of SLPI than
HDs, but signiﬁcant differences were not detected (Figure 1B).
IFN-g Levels in Plasma from HD and TB Patients
Because the severity of TB disease is associated with a
reduced T-cell IFN-g production,23 we next analyzed the
plasma levels of this cytokine in TB patients and HD sub-
jects. Figure 2A shows that IFN-g levels were signiﬁcantly
higher in patients compared with HDs. Therefore, although
Mtb-Agestimulated PBMCs from TB patients had dimin-
ished IFN-g production, compared with healthy tuberculin
reactors,23 plasma levels of this cytokine are augmented
during active disease, as previously reported.24,25 Further-
more, we found a positive correlation between IFN-g and
SLPI levels in plasma of TB patients (Pearson coefﬁcient:
r Z 0.532, P < 0.05), but not in HD subjects (Pearson
coefﬁcient: r Z 0.024, P > 0.05) (Figure 2B).
Effect of IFN-g on SLPI Levels
It is known that IFN-g inhibits the production of SLPI in HD
subjects20 and that Mtb-Agestimulated PBMCs increase
IFN-g production.26 Therefore, we speculated that the
increased secretion of IFN-g induced byMtb-Ag in vitromight
decrease the production of SLPI in HD and TB patients. To
investigate this, PBMCs were cultured with Mtb-Ag and SLPI
levels were measured in cell culture supernatants. Mtb-Ag
stimulation of PBMCs from HDs decreased SLPI levels in
culture supernatants (Figure 3A). Moreover, when Mtb-
Agestimulated cells fromHDs were incubated with a blocking
antibody against IFN-g, the levels of SLPI were restored
(Figure 3A). However, when PBMCs from TB patients were
stimulated with Mtb-Ag or blocking antieIFN-g antibody, no
modiﬁcation of the levels of SLPI was detected (Figure 3A).
Even more, the addition of rIFN-g to cultures withMtb-Ag did
not modify the levels of SLPI production by TB patients.
IFN-g signals are mediated through its heterodimeric re-
ceptor, a molecule down-modulated in patients with active TB
but restored on anti-TB therapy.27 Then, we wondered
whether the absence of signaling through IFN-gR could be
responsible for the ineffectiveness of IFN-g on modifying the
production of SLPI by TB patients. To this end, we investi-
gated the levels of SLPI produced by two patients with
IFNGR1mutation, in response toMtb-Ag stimulation.Mtb didThe American Journal of Pathology - ajp.amjpathol.orgnot modify the amount of SLPI produced by PBMCs from
IFNGR1* patients, suggesting that signaling through IFN-gR
modulates SLPI expression and secretion (Figure 3B). Given
that SLPI levels were associated with TB severity, we further
measured the expression of IFN-gR by real-time PCR in pa-
tients with mild, moderate, and severe TB. Among TB pa-
tients, individuals with severe disease displayed the lowest
amounts of IFN-gR (Figure 3C).
Finally, to verify in our physiologicalmodel that the absence
of SLPI inhibition in TB patients was mediated by the down-
modulation of the expression of IFN-gR, we next evaluated by
real-time PCR the levels of IFN-gR in PBMCs from TB
patients and HDs, treated with Mtb-Ag. PBMCs from TB
patients cultured overnight with Mtb-Ag expressed sig-
niﬁcantly lower levels of IFN-gR compared with HDs
(Figure 3D). Interestingly, these differences were not observed
after 24 or 48 hours of antigen stimulation of the cells1271
Tateosian et al(Figure 3D), probably because in vitro, the levels of IFN-gR
were down-modulated during the time of cell culture. Taken
together, our ﬁndings indicate that TB patients are unable to
modulate the expression of SLPI, further suggesting that the
anti-mycobacterial activity of SLPIwould not be compromised.
Discussion
SLPI is a secreted pattern recognition receptor for Mtb
detected in sputum from patients with active disease.18 In the
present study, we found that both SLPI and IFN-g were
signiﬁcantly enhanced in plasma from TB patients compared
with HDs. Furthermore, our ﬁndings demonstrated a direct as-
sociation between SLPI levels and the severity of TB disease.
Stimulation of PBMCs with Mtb antigen signiﬁcantly dimin-
ished the levels ofSLPIproducedbyHDsbut didnotmodify the
production of SLPI by patients with active disease or patients
with mutation in IFNGR1. Moreover, neutralization of endog-
enous IFN-g reversed the inhibition of SLPI induced by Mtb
in HDs, whereas rIFN-g was unable to modify the expression
of SLPI in TB patients. Furthermore, our data showed that
IFN-gR was expressed at lower levels in TB patients.
The anti-mycobacterial activity of SLPI either in vitro or
in vivo has been described.17,18 SLPI was also shown to
decrease cell-mediated immunity.28,29 More important, SLPI
inhibited IFNg-induced NF-kB activation in macrophages of
patients with chronic obstructive pulmonary disease.30
Considering that cell-mediated immunity is critical in the im-
mune response of the host toMtb, in particular IFN-g produc-
tion,31 the mentioned reported results preclude the possible use
of SLPI as a new therapeutic drug in human TB. However, our
present ﬁndings show, for the ﬁrst time to our knowledge, that,
in contrast to HD subjects, TB patients are unable to modify
SLPI production in response to IFN-g. Consistent with our re-
sults, differences in thebehavior of other immune cells fromHD
subjects and TB patients have been previously shown,32,33
although the mechanisms underlying those defects were un-
clear. Herein, we observed an association between the levels of
plasma SLPI and the severity of TB disease (Figure 1B).
Actually, the levels of IFN-g in the serum of TB patients
correlated with SLPI concentration (Figure 2B). In particular,
this later correlation reinforces our in vitro results showing that
IFN-g fails to inhibit SLPI production inTBpatients, in contrast
to data described for murine cells.34 Our results also demon-
strated an absence of modulation of SLPI levels by IFN-g in
Mtb-stimulated cells from TB patients (Figure 3A).
Functional IFN-gR included two ligand-binding IFNGR1
chains associated with two signal-transducing IFNGR2 chains
and belongs to the class II cytokine receptor family, a class of
receptors that bind ligand in the small angle of a V formed by
the two Ig-like folds that constitute the extracellular domain.4
One of the major mechanisms used by the body to regulate
the strength and duration of IFN-g responses is through the
modulation of the levels of its receptor.Accordingly, the down-
modulation of IFN-gR surface protein and mRNA expression
has been demonstrated in PBMCs fromTBpatients exposed to1272live Mtb.27 Consistent with those reports, we also observed a
decrease in IFN-gR mRNA levels associated with the severity
of TB disease (Figure 3C) and a time-dependent down-mod-
ulation of IFNGR transcripts in TB patients (Figure 3D).
Probably, those changes in the expression of IFN-gRmight be
related to the levels of IFN-g present in the medium.
Loss of functional IFNGR1 appears to be associated with an
increased susceptibility to some viruses and intracellular bac-
terial infection. Patients with inactivating mutations of
IFNGR1 or IFNGR2 chains often present severe susceptibility
to poorly virulent mycobacteria, such as early-onset bacille
Calmette-Guerin infection in childhood.4,35 Experiments con-
ducted with PBMCs from IFNGR1* patients suggested that
signaling through this receptor would trigger the mechanism
required to perform SLPI inhibition, because the absence of
signaling through IFN-gR impaired the decrease in the levels of
SLPI (Figure 3B). Similar to other receptor-cytokine systems,
the ability of a cell to respond to IFN-g depends on the level of
expression of its receptor and on its functionality.36 Thus, the
low expression of IFN-gR in PBMCs from TB patients would
alter the IFN-gespeciﬁc responsiveness of the target cell.
Finally, we postulate that the high levels of SLPI in patients
with active disease might help to eliminate Mtb through its
microbicidal activity.17,18 However, further work would be
necessary to unravel the effect of SLPI on IFN-g expression.
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